Discovery Development Programs

The in-house development programs at Bioasis are designed to develop effective treatments for patients suffering with neurological diseases. The goal of these programs is to produce symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis is a science-driven company focused on neuroscience research. Our research advances the science of transporting medicine into the brain and creates a path to develop therapies for hundreds of central nervous system (CNS) diseases that were previously untreatable.

Our strategy is to do the right research at the right time and for the right reasons—a focus designed to deliver success. We will advance our clinical studies when we are certain we have achieved the appropriate outcome to inform a “go” or “no-go” decision based on the data generated through our carefully designed research programs.

Bioasis-supported research and development are the output from the exchange of ideas with preeminent researchers at leading academic institutions, our scientific advisory board and our biopharmaceutical collaborators. Research based on the xB3 platform has achieved success in the transport of dozens of compounds across the blood-brain barrier in both in-vitro and in-vivo studies. We have conducted research studies at more than 20 leading research institutions and biopharmaceutical companies. Data from these studies are available for review and discussion with our research experts and will form the foundation for new research programs.

xB3-001: Brain Metastases

Brain metastases are among the most common form of brain cancer in adults. For example, HER2-positive breast cancer has a high incidence of the cancer spreading from its primary site in the breast to the brain. The prognosis for these brain metastases is often fatal as the resulting brain tumors are largely untreatable because anti-cancer drugs cannot cross the blood-brain barrier at effective levels.

xB3-002: Glioblastoma

Glioblastoma is one of the most aggressive cancers that originates within the brain, and 80 percent of diagnosed primary malignant brain tumors are malignant gliomas. Glioblastoma is considered the deadliest form of brain cancer due to its high infiltration of surrounding brain tissue. The standard treatment involves invasive surgical removal of tumors accompanied by subsequent radiation and chemotherapeutic treatments, which has remained unchanged for decades as most drugs are unable to cross the blood-brain barrier to act on the tumor.

Our proprietary xB3 platform technology offers the opportunity to turn non-brain-penetrating anti-cancer drugs into new entities that will be able to cross the blood-brain barrier, seek out cancer tumors in the brain and slow or stop their growth. Based on our success in rodent models, we are focused on taking our xB3-001 and xB3-002 programs forward by confirming biodistribution in non-human primate models, utilizing the recent advancement in PET imaging. Furthermore, we are moving forward to engage toxicity studies to enable us to find the right dose and safety level that will translate to humans.

xB3-003: Parkinson’s Disease

Parkinson’s disease is a chronic and progressive degenerative disorder of the central nervous system affecting mainly the motor system. The cause of the disease is not yet known; however, the most common known genetic mutation associated with Parkinson’s disease has been indicated to be the glucocerebrosidase (GBA1) gene mutation. It has been proposed that people carrying the GBA1 mutation possess a 20-to-30-fold higher risk of developing Parkinson’s disease, with up to 10 percent of Parkinson’s patients carrying the GBA1 mutation. This mutation represents the most important risk factor for the disease, with slightly earlier onset age and more aggressive in terms of cognitive impairment compared to idiopathic Parkinson’s disease.

Our xB3-003 program offers the potential to significantly improve the delivery of drugs targeting the GBA1 mutation in the brain in a non-invasive manner, accompanied by reduction in the side effects and complications associated with the dose used. We aim to confirm the brain payload delivery capability of xB3 using advanced PET imaging in non-human primate models, accompanied by examining the overall effect on the brain by looking at neurochemistry and conducting functional MRI (fMRI).